arrow
T

Tsuyoshi Shirakawa

clinical hematology oncology treatment study group
H指数:15
被引数:749

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Relationship between initial dose, dose intensity, and survival in unresectable pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid

不可切除胰腺癌患者接受纳米脂质体伊立替康、氟尿嘧啶和甲酰四氢叶酸治疗后初始剂量、剂量强度与生存率之间的关系

2026-08-110
OAAI
Effect of biliary drainage and biliary tract infection in unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: a multicenter, prospective cohort study (NAPOLEON-2)

纳米脂质体伊立替康联合氟尿嘧啶和甲酰四氢叶酸治疗不可切除性胰腺癌中胆道引流和胆道感染的影响:一项多中心、前瞻性队列研究(NAPOLEON-2)

2026-05-260
OAAI
Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study)

不可切除或复发性胰腺癌患者使用纳米脂质体伊立替康联合氟尿嘧啶和亚叶酸钙(NAPOLEON-2研究)中预测长期无进展生存期的因素

2026-04-210
PRE
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study

术前化疗对纳米脂质体伊立替康联合氟尿嘧啶和甲酰四氢叶酸用于不可切除胰腺癌的影响:一项基于多中心NAPOLEON-2研究数据的回顾性分析

2025-11-180
OA
Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 Study
2025-11-010
PRE
Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid

化疗诱导的中性粒细胞减少预测接受纳米脂质体伊立替康、氟尿嘧啶和甲酰四氢叶酸治疗的胰腺癌患者的短期结局

2025-08-010
PRE
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)

纳米脂质体伊立替康与叶酸辅助氟尿嘧啶在胰腺癌患者中治疗前后炎症标志物的比较:NAPOLEON-2 研究 (NN-2302) 的结果

2025-02-210
OA
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)
2025-01-270
OAAI
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
2024-07-230
OAAI
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer
2024-05-303
OAAI
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel (vol 13, 8815 , 2023)
2024-03-040
OAAI
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
2023-11-087
OAAI
Efficacy of third-line chemotherapy after liposomal irinotecan and fluorouracil with folinic acid for pancreatic cancer
2023-11-010
OA
Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan
2023-10-310
OAAI